TY  - JOUR
AU  - Ng, Alexander B C D
AU  - Asif, Aqua
AU  - Agarwal, Ridhi
AU  - Panebianco, Valeria
AU  - Girometti, Rossano
AU  - Ghai, Sangeet
AU  - Gómez-Gómez, Enrique
AU  - Budäus, Lars
AU  - Barrett, Tristan
AU  - Radtke, Jan Philipp
AU  - Kesch, Claudia
AU  - De Cobelli, Francesco
AU  - Pham, Tho
AU  - Taneja, Samir S
AU  - Hu, Jim C
AU  - Tewari, Ash
AU  - Rodríguez Cabello, Miguel Á
AU  - Dias, Adriano B
AU  - Mynderse, Lance A
AU  - Borghi, Marcelo
AU  - Boesen, Lars
AU  - Singh, Paras
AU  - Renard-Penna, Raphaële
AU  - Leow, Jeffrey J
AU  - Falkenbach, Fabian
AU  - Pecoraro, Martina
AU  - Giannarini, Gianluca
AU  - Perlis, Nathan
AU  - López-Ruiz, Daniel
AU  - Kastner, Christof
AU  - Schimmöller, Lars
AU  - Rossiter, Marimo
AU  - Nathan, Arjun
AU  - Khetrapal, Pramit
AU  - Chan, Vinson Wai-Shun
AU  - Haider, Aiman
AU  - Clarke, Caroline S
AU  - Punwani, Shonit
AU  - Brew-Graves, Chris
AU  - Dickinson, Louise
AU  - Mitra, Anita
AU  - Brembilla, Giorgio
AU  - Margolis, Daniel J A
AU  - Takwoingi, Yemisi
AU  - Emberton, Mark
AU  - Allen, Clare
AU  - Giganti, Francesco
AU  - Moore, Caroline M
AU  - Kasivisvanathan, Veeru
TI  - Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.
JO  - The journal of the American Medical Association
VL  - nn
SN  - 0254-9077
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2025-01888
SP  - nn
PY  - 2025
N1  - epub
AB  - Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.To assess whether biparametric MRI is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer.A prospective, multicenter, within-patient, noninferiority trial of biopsy-naive men from 22 centers (12 countries) with clinical suspicion of prostate cancer (elevated prostate-specific antigen [PSA] level and/or abnormal digital rectal examination findings) from April 2022 to September 2023, with the last follow-up conducted on December 3, 2024.Participants underwent multiparametric MRI, comprising T2-weighted, diffusion-weighted, and dynamic contrast-enhanced (DCE) sequences. Radiologists reported abbreviated biparametric MRI first (T2-weighted and diffusion-weighted), blinded to the DCE sequence. After unblinding, radiologists reported the full multiparametric MRI. Patients underwent a targeted biopsy with or without systematic biopsy if either biparametric MRI or multiparametric MRI was suggestive of clinically significant prostate cancer.The primary outcome was the proportion of men with clinically significant prostate cancer. Secondary outcomes included the proportion of men with clinically insignificant cancer. The noninferiority margin was 5
LB  - PUB:(DE-HGF)16
C6  - pmid:40928788
DO  - DOI:10.1001/jama.2025.13722
UR  - https://inrepo02.dkfz.de/record/304499
ER  -